Search

In this review we summarize the characteristic features of multiple eruptive dermatofibromas based on an analysis of cases in the literature. Many researchers have reported multiple eruptive dermatofibromas diagnosed using the definition of "multiple" as the presence of at least 15 lesions. However, this criterion is arbitrarily chosen and might not be entirely valid for all cases. A more precise definition may include the eruption of several multiple eruptive dermatofibromas reported within a short period of time. Because more than half of the patients with multiple eruptive dermatofibromas have underlying diseases, and more than 80% of the underlying diseases are immunemediated, multiple eruptive dermatofibromas could possibly be considered as a partial manifestation of an immune-mediated disease. This underscores the possibility of early diagnosis of immune-mediated diseases in patients with multiple eruptive dermatofibromas. [ABSTRACT FROM AUTHOR]

Numerous surgical methods have been introduced to treat osmidrosis. However, many problems with wound healing have been reported, including haematoma, seroma, skin necrosis and severe scarring. Ultrasound energy liquefies sweat glands via cavitation, but minimally affects blood vessels and nerves at the same energy level. Our patient was treated with ultrasonic surgical aspiration, which allowed the effective removal of the apocrine glands with little scarring. The ultrasonic surgical aspirator offers a safe and effective method to treat osmidrosis with few complications. This is the operation of first choice, especially for the patients who are sensitive about their surgical scars. [ABSTRACT FROM AUTHOR]

The article presents a case study of a 71-year-old man having pigmented macules of one month duration. Microscopic examination revealed sheets of cells abundant eosinophilic cytoplasm, enlarged nuclei and several mitotic figures. Immunohistochemical studies were negative for CD56, CD20, CD8, CD4 and CD3, and positive for lysozyme, myeolo-peroxidase, CD45 and CD43, which confirms myeloid sarcoma diagnosis.